Search

THE PREVALENCE of clinically meaningful conjunctivitis in patients taking dupilumab for atopic dermatitis (AD) is likely about 2%, and it most often occurs in the first 16 weeks of therapy [...]

Abstract Atopic dermatitis (AD) has a significant, lifelong clinical impact on affected individuals and has profound effects on quality of life both for patients and their families. The diagnosis usually [...]

PATIENTS WITH ATOPIC dermatitis might face up to a 44% increased risk of suicidal ideation and are 36% more likely to attempt suicide than those without the disorder, a large [...]

WITH THE DISCOVERY of how cytokines such as IL-4, IL-5, IL-13, and IL-31 drive inflammatory disease pathogenesis, more targeted therapies are possible for dermatologic conditions such as atopic dermatitis. The [...]

EXPERT ANALYSIS FROM THE EADV CONGRESS VIENNA -- Topical crisaborole 2% ointment administered twice a day was consistently associated with clinically meaningful quality of life improvement scores on multiple measures [...]

AT THE 2016 SID ANNUAL MEETING SCOTTSDALE, ARIZ. -- Among patients with atopic dermatitis, persistently active disease was significantly more common among females of nonwhite race with a history of [...]

FROM THE BRITISH JOURNAL OF DERMATOLOGY PATIENTS WITH ATOPIC DERMATITIS are at an increased risk of Staphylococcus aureus colonization of both their lesional and nonlesional skin, as well as their [...]

LOS ANGELES -- A new Cochrane systematic review and meta-analysis has concluded there is no consistent evidence that specific allergen immunotherapy is beneficial in patients with atopic dermatitis, Dr. Herman [...]